This review of individual patient data evaluated the effect of prenatal treatment for congenital toxoplasmosis on motherto-child transmission and infants' clinical manifestations. Treatment was associated with a lower rate of mother-to-child transmission, but did not change the risk of clinical manifestations. The authors stated that randomised clinical trials are needed to confirm these findings. These conclusions are likely to be reliable.
Participants included in the review
Studies of pregnant women screened positive for Toxoplasma gondii infection during pregnancy by universal screening were eligible for inclusion. Cohort studies with retrospective testing for maternal infection were excluded. The precise dates of testing and start of prenatal treatment were required for a study to be included. Studies of mothers enrolled before 1985 were excluded. For the analyses of clinical manifestations in children, only European cohorts of liveborn children with congenital toxoplasmosis were considered.
Outcomes assessed in the review
Studies assessing mother-to-child transmission and/or infants' clinical manifestations were eligible. Clinical manifestations were defined as ocular lesions, intracranial lesions, or both, and to be eligible, studies of clinical manifestations had to perform at least one ophthalmoscopy or intracranial imaging examination during the first year of life.
How were decisions on the relevance of primary studies made?
Two reviewers independently selected the studies. The authors did not state whether trial investigators were contacted to verify uncertain eligibility. The authors did not state how and whether any inconsistency or missing data were verified with the trial investigators. Four reviewers examined the IPD before deciding whether to include a trial.
Assessment of study quality

Data extraction
The authors did not state whether trial investigators were contacted to verify the finalised data.
Methods of synthesis
How were the studies combined? Pooled odds ratios (ORs) and their confidence intervals (CIs) were calculated using a fixed-effect logistic regression model and checked with a random-effects model. Only results obtained with the fixed-effect model were presented since the use of the random-effects model did not modify the findings. An integrated maximum likelihood method was used to account for gestational age at seroconversion and timing of treatment initiation.
How were differences between studies investigated?
The effect of gestational age at seroconversion, the latitude of the centre, and the period during which the study was conducted (before 1991, between 1991 and 1994, and after 1994) on the pooled estimates was considered in the analysis using the likelihood ratio test. The effect of timing and type of prenatal treatment was examined in subgroup analyses. Sensitivity analysis was performed to test the robustness of the results by the method used to estimate the gestational age at seroconversion.
Results of the review
The IPD from 14 studies (including IPD for 20 cohorts of 1,721 women and 26 cohorts of 550 infants) were included in the review. The authors stated that other eligible trials were identified, but one trialist refused to participate and the investigators of 4 studies did not respond.
Mother-to-child transmission.
The risk of mother-to-child transmission increased with gestational age at seroconversion (OR 1.15 per week, 95% CI: 1.12, 1.17). Prenatal treatment was associated with a lower risk of transmission (OR 0.94 per week, 95% CI: 0.90, 0.98), especially when treatment was started early after the mother's seroconversion. The odds of transmission also decreased significantly with higher (5 degrees) latitude (OR 0.71, 95% CI: 0.53, 0.96). Rates of mother-to-child transmission were not significantly different when patients were treated with spiramycin compared with pyrimethaminesulphonamide (OR 0.79, 95% CI: 0.55, 1.13). Clinical manifestations.
Higher gestational age at seroconversion was associated with a lower risk of overall clinical manifestations (OR 0.96 per week, 95% CI: 0.93, 0.99, p=0.01), intracranial lesions (OR 0.91 per week, 95% CI: 0.87, 0.95) and ocular lesions (OR 0.97 per week, 95% CI: 0.93, 1.00, p=0.04) in infancy. The risk of any clinical manifestations was comparable between infants of treated and untreated mothers (OR 1.11, 95% CI: 0.61, 2.02). Correcting for the type of treatment, period of the study, or the latitude of the centre did not modify these findings. The combination of spiramycin and pyrimethamine-sulphonamide carried a higher risk of any clinical manifestations than pyrimethamine-sulphonamide alone (OR 1.29, 95% CI: 1.42, 9.34 ).
